Get started
Moderna, Inc.Moderna, Inc.Moderna, Inc.

Moderna, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

MRNA trade ideas

3/22 Watchlist + NotesSPY - Once again we were bullish going into today and ended up getting that upside movement we wanted. Tomorrow is FOMC so no real prediction for tomorrows movement other than some chop leading up to the news. As far as the news goes, I am leaning more on the bullish side but quite honestly that is purely a guess. Trading light tomorrow if I take anything, and not trading after news comes out. Watchlist: MRNA - 3-1: Bullish BIDU - 2-1: Neutral Main Watch: MRNA - Nothing special about this setup other than it being a 3-1 daily setup and seeing that it has more room to the upside to test a daily FVG around 157.70 Top winner from yesterdays watchlist: GOOG - 2-1 daily broke to the upside and had a gorgeous uptrend day. Calls ran just under 240% from where the long entry (yesterdays high) was
NASDAQ:MRNA
by Alanger17
$MRNA What Up$MRNA started playing this since it was in the low $20s and then got rid of it at the start of this year. And IMO this is headed under $100. It will get a kick start when the next Pandemic happens and WHO rules lockdowns across the world. Regardless of the hype, I don't see any reason to take a position in this ticker. The only outcome is, EXIT for me :) Although it does have a promising technology but it will not be able to generate the kind of revenue it did with the Pandemic vax
NASDAQ:MRNAShort
by VIN786
MRNA | This is a BUY | BOUNCEModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by DivergenceSeeker
3
Moderna (MRNA) ... Time for a shot in the Arm ?Moderna (MNRA). This is a potential long trade if it reaches my area of interest in my PRZ (price reversal zone). A nicely formed ABCD formation together with a Harmonic Crab / Alternate Bat (depending where X starts), come together in the mid to low $160s. (This also happens to come full circle to the recent December 2022 low.) This together with positive momentum hopefully sets up one or both of the targets objectives. I wouldn't chase this and beware of broader markets. Earnings are expected Feb. 23rd at $4.70. As always DYODD. I will monitor S,
NASDAQ:MRNA
by Steve666
Bullish Crossover for MRNA Share Appears in the HorizonModerna's share (MRNA) price has been running in a narrow price range since November 8 after a series of gains extending since October 21, surpassing the short and long-term exponential moving averages in a positive short-term sign. Meanwhile, an unclear zigzag path has dominated MRNA share since the beginning of the year. As for now, and on the daily chart, we keep an eye on 180.13 and $198.82 as possible bullish targets, as we await the bullish crossover of the MA-25 and MA-50 to achieve the possible bullish path. On the flip side, if MRNA share price fails to stabilize above the $162 level, the previous bullish hypothesis may be invalidated, and we may witness a pullback towards $142-135 levels (yellow shaded area).
NASDAQ:MRNALong
by SamerHa